GT Biopharma set for best day in over 3 months on tumor therapy trial update
08/12/2021 14:06
** Drug developer's GTBP.O shares jump ~13% to $3.9
premarket
** Stock set for best day in more than three months
** Co says its drug candidate, GTB-5550, induces natural
killer cell activation against a broad spectrum of tumors in a
pre-clinical study
** Natural killer cells form part of the body's immune
system and help fight infection and cancer
** Co says the candidate also showed broad activity against
B7-H3, a glycoprotein that is overexpressed in several solid
tumors
** Up to Tuesday's close, stock down ~52% YTD
(Reporting by Dania Nadeem in Bengaluru)
((Dania.Nadeem@thomsonreuters.com;))